N-[(1-乙基-3-吡咯烷)甲基]-1-乙胺 | 959239-18-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-[(1-乙基-3-吡咯烷)甲基]-1-乙胺
• 英文名称: N-[(1-Ethylpyrrolidin-3-YL)methyl]ethanamine
• CAS: 959239-18-0
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: JMAGSGRQNWLQKT-UHFFFAOYSA-N

物化性质

• 沸点：
  195.9±8.0 °C(Predicted)
• 密度：
  0.866±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090

文献信息

• [EN] COMPOUNDS FOR USE IN STABILISING p53 MUTANTS<br/>[FR] COMPOSÉS PERMETTANT DE STABILISER LES MUTANTS DE P53
  申请人：MEDICAL RES COUNCIL

  公开号：WO2012175962A1

  公开（公告）日：2012-12-27

  Provided are compounds for use in a method of treatment of a subject who has a lesion or a tumour in which p53 carries a Y220C mutation, in which the compound is selected from compounds of the following formula (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof: (I) R: where A is CR4 or N; -R-1 is selected from -OH, -OMe, -NH2, -SH, -F and -CF3; -R2 is selected from -CI, -Br, -I, and ethynyl (-C≡CH); -R3 is selected from -I, -Br, -CI, ethynyl (-C≡CH), -R35, -H, -OMe, and -N02; wherein -R3S is selected from: and -R5 is selected from -COOH and: 8A formula Ilia formula 1Mb formula 111 o 3 where -R6, -R7A, - R7B, -Rs, and -R8A are as defined in the specification. Compounds of formula (I) are also provided, as is their use in methods of treatment, and methods for their preparation.

  提供了用于治疗患有p53携带Y220C突变的病变或肿瘤的方法中使用的化合物，其中该化合物从以下公式(I)的化合物中选择，并且其药学上可接受的盐、水合物和溶剂化合物：(I) R：其中A为CR4或N；-R-1选择自-OH、-OMe、-NH2、-SH、-F和-CF3；-R2选择自-Cl、-Br、-I和乙炔（-C≡CH）；-R3选择自-I、-Br、-Cl、乙炔（-C≡CH）、-R35、-H、-OMe和-N02；其中-R3S选择自：和-R5选择自-COOH和：8A公式Ilia公式1Mb公式111 o 3其中-R6、-R7A、-R7B、-Rs和-R8A如规范中所定义。还提供了公式(I)的化合物，以及它们在治疗方法中的使用和制备方法。
• Fused quadracyclic compounds, compositions and uses thereof
  申请人：Tabomedex Biosciences, LLC

  公开号：US10562909B2

  公开（公告）日：2020-02-18

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

  本发明提供了可用作 MK2 抑制剂的取代融合四环化合物。本发明进一步提供了本发明化合物的药物组合物。本发明还提供了取代的融合四环化合物的医疗用途。
• [EN] FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS QUADRACYCLIQUES CONDENSÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
  申请人：TABOMEDEX BIOSCIENCES LLC

  公开号：WO2017120164A1

  公开（公告）日：2017-07-13

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.